XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

XTX Topco Ltd lifted its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 241.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,008 shares of the company's stock after acquiring an additional 31,844 shares during the quarter. XTX Topco Ltd's holdings in 10x Genomics were worth $1,016,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of 10x Genomics by 134.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock valued at $32,000 after purchasing an additional 939 shares during the period. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock valued at $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics in the 3rd quarter valued at approximately $35,000. First Horizon Advisors Inc. grew its stake in shares of 10x Genomics by 74.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock valued at $37,000 after purchasing an additional 808 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after purchasing an additional 1,025 shares during the period. Institutional investors own 84.68% of the company's stock.

10x Genomics Price Performance

TXG traded down $0.07 during trading on Wednesday, hitting $16.08. 739,276 shares of the stock traded hands, compared to its average volume of 1,735,038. 10x Genomics, Inc. has a twelve month low of $12.95 and a twelve month high of $57.90. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -10.56 and a beta of 1.84. The business has a 50 day moving average price of $16.02 and a 200 day moving average price of $19.10.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company's revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share. On average, equities research analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Wall Street Analyst Weigh In

TXG has been the topic of a number of recent research reports. UBS Group decreased their price objective on 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. The Goldman Sachs Group decreased their price objective on 10x Genomics from $16.00 to $14.00 and set a "sell" rating on the stock in a research report on Wednesday, October 30th. Canaccord Genuity Group decreased their price objective on 10x Genomics from $32.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, October 10th. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of 10x Genomics in a research note on Thursday, October 10th. Finally, Leerink Partnrs raised 10x Genomics to a "strong-buy" rating in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.19.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.